Biohaven Ltd.

Biohaven is legally organized in the British Virgin Islands, with its U.S. operating subsidiary based in New Haven, Connecticut and an Irish subsidiary supporting operations and tax structure. The company’s development work is centered in the United States and Ireland, which are the locations specifically referenced in its tax and operating disclosures. Because Biohaven is still pre-commercial, geography matters more for where R&D is performed and where subsidiaries are taxed than for where product sales are generated. The company has not disclosed country-level revenue because it has not yet generated product sales. Its geographic exposure is therefore concentrated in U.S. and Irish operating costs, regulatory oversight, and future commercialization pathways.

Biohaven faces the classic risks of a clinical-stage biopharmaceutical company: it has no product revenue, significant operating losses, and a continuing need for capital to fund development. The company depends heavily on third parties for preclinical studies, clinical trials, manufacturing, and distribution, so delays or quality issues at vendors can directly slow the pipeline. Regulatory risk is material because approval timing, orphan exclusivity, and FDA review outcomes determine whether any candidate can become a commercial product. Intellectual property risk is also important because the value of the pipeline depends on patent protection and freedom to operate. More broadly, macroeconomic conditions, inflation, and capital-market volatility can affect supplier costs, partner economics, and Biohaven’s ability to raise funds on acceptable terms.